Compare

Hexarelin vs Tesamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

Hexarelin

24 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 97% · Mixed 3% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
143
Sleep
143
Energy
78

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
5

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 100–400 mcg

100–200
84
200–400
59

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 148 days · Based on 23 repeat reporters

Tesamorelin

114 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
224
Sleep
1
Recovery
1
Libido
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site irritation
113
Water retention
106

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 1–2 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 46 days · Based on 41 repeat reporters

Sources (11)

Published sources linked on the Hexarelin and Tesamorelin wiki pages.

  1. PubMed

    Hexarelin, a synthetic growth hormone-releasing peptide, vs GHRH in GH-deficient adults

    Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996

    Source
    Wiki study page →

  2. PubMed

    Hexarelin provides cardioprotective effects in rats

    Bisi G, Podio V, Valetto MR, et al. Growth Horm IGF Res. 2001

    Source
    Wiki study page →

  3. ClinicalTrials.gov

    Hexarelin studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →

  5. PubMed

    The cardiovascular action of hexarelin

    Mao Y, Tokudome T, Kishimoto I. Journal of geriatric cardiology : JGC. 2014

    Source
    Wiki study page →

  6. FDA Drug Label

    EGRIFTA (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2010

    Source
    Wiki study page →

  7. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →

  8. ClinicalTrials.gov

    Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →

  9. FDA Drug Label

    EGRIFTA SV (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2019

    Source
    Wiki study page →

  10. PubMed

    Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

    Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012

    Source
    Wiki study page →

Explore other peptides